Vapogenix is developing a new class of locally acting non-opioid medications to treat pain
Houston, TX
Joined May 2018
- Tweets14
- Following73
- Followers50
- Likes8
Dr. Heather Giles, Chief Scientific Officer of Vapogenix, will present a talk entitled "An overview of volatile anesthetics and their applications in pain therapeutics" at the Pain Therapeutics 2021 Virtual Conference on Tuesday, May 10, 2021.
Clinical data from Vapogenix’s lead program, “Analgesic efficacy, safety and tolerability of VPX638 (sevoflurane) administered topically to patients with painful wounds”, will be reported by Dr. Michael Woodward of Wound Clinic, Austin Health at Wounds Australia 2020 on 5/5/21.
@vapogenix There is a real clinical imperative to develop alternatives to opioids for the more than 30 million patients suffering from painful inflammatory conditions.
Details: bwnews.pr/3lnuJ8K
#arthritis #painmanagement #rheumatoidarthritis #opioids #painmanagement
Promising news about sevoflurane as a topical treatment for pain!
medscape.com/viewarticle/934…
Going to #JPM2020? @vapogenix CEO Heather Giles, @heather92219925 will be there to talk about our novel non-opioid topical pain medications.
Get in touch at [email protected] or +1-713-748-3903
#jpm #opioidcrisis #pain
Vapogenix Inc. CEO @heather92219925, will be at #JPM2020 meeting with partners and investors to talk about Vapogenix pipeline of topical non-opioid pain drugs.
Contact Heather Giles at [email protected] or +1-713-748-3903.
#opioidcrisis #pain
Meet up with Dr. Heather Giles, CEO of Vapogenix Inc at #Pharmacology2019 @BritPharmSoc to learn more about Vapogenix's non-opioid topical analgesics
Vapogenix will be present at the BIO-Europe® 2019 meeting in Hamburg, Germany from November 11th to 13th
We are seeking partners and funding to advance our portfolio programs.
For further information: vapogenix.com/news.html
Vapogenix attended the Texas Life Science Forum 2019. Wonderful event! Kudos to the organizers.
#TLSF2019 @BioHouston @ricealliance
Vapogenix is presenting at the Texas Life Science Forum in Houston on Wednesday November 6th, 2019
"Uncovering Strategies for Planning and Executing a Clinical Trial in Australia"
#TXLSF #Pain #Australiaclinicaltrials
Vapogenix Inc retweeted
#IrishAngelsPortCo @vapogenix has announced results of a Phase II clinical trial for its lead product, which demonstrates rapid onset and sustained duration of pain relief and reduced opioid use of patients – via @biospace ow.ly/ZoiI50wXe7f
Vapogenix Inc retweeted
#Vapogenix announced results of a phase II clinical trial. The data strongly suggests that this novel class of non-opioid analgesics has the potential to provide substantial pain relief for non healing painful ulcers #nonopioidpainrelief businesswire.com/news/home/2…
Today announced results of Phase II trial of our lead product, VPX638, a topical non-opioid, lidocaine-free analgesic. Data reveals VPX638 significantly reduces pain and use of opioids. Read more: bwnews.pr/2NgzHUM #opioidcrisis #painrelief #painmanagement
